new glp 1 drug retatrutide Promises Big Weight Loss, but Safety Remains a Question What You Need to Know

Here is how the quality tiers typically break down

About one in seven adults who have ever used GLP-1 medications say they are no longer using these drugs because of the cost (14%), similar to the share who report no longer taking the medications because of side effects (13%)

Retatrutide has not been compared head-to-head with earlier GLP-1 medications in any clinical trials, although there is an ongoing trial called TRIUMPH-5, which is comparing it with tirzepatide

Any retatrutide obtained outside of a formal, ethics-approved clinical trial is classified as a research chemical and is not intended for human use under current UK regulations

8.7 Hepatic Impairment There is limited experience in patients with mild, moderate or severe hepatic impairment

Patients should seek urgent medical advice if hair loss is accompanied by scalp pain, redness, scaling, or complete bald patches